Stage IV Rectal Cancer

TAS-102 Improves Survival in Advanced Colorectal Cancer (07-9-2014)

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on... Continue Reading

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer (06-20-2014)

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or... Continue Reading

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (03-5-2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment... Continue Reading

Erbitux Plus Chemo Boosts Survival in Patients with Colorectal Cancer and Liver Metastases (05-29-2013)

Adding Erbitux® (cetuximab) to standard chemotherapy might allow some patients with colorectal cancer and inoperable liver metastases to undergo successful surgical resection of the liver metastasis, according to the results of a study published in the Journal... Continue Reading

Aspirin May Prolong Life in PIK3CA-Mutated Colorectal Cancers (11-6-2012)

Daily aspirin use improves survival among patients with mutated-PIK3CA colorectal cancer, according to the results of a study published in the New England Journal of Medicine. Colorectal cancer remains the second leading cause of cancer-related death... Continue Reading

Zaltrap Approved for Metastatic Colorectal Cancer (08-15-2012)

The U.S. Food and Drug Administration (FDA) has approved Zaltrap® (ziv-aflibercept) for use in combination with the FOLFIRI chemotherapy regimen (folinic acid, fluorouracil, and ironotecan) to treat adults with metastatic colorectal cancer. Colorectal... Continue Reading

Continued Avastin Extends Survival After First Progression in Advanced Colorectal Cancer (06-14-2012)

Combined second-line treatment with Avastin® (bevacizumab) and standard chemotherapy extends survival in patients with advanced colorectal cancer who have received first-line combined Avastin treatment, according to the results of a large phase III study... Continue Reading

Regorafenib Shows Promise Against Metastatic Colorectal Cancer (01-19-2012)

The investigational drug regorafenib improves survival and delays cancer progression among patients with metastatic colorectal cancer that has worsened in spite of other treatments. These results will be presented at the 2012 Gastrointestinal Cancers... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (11-16-2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Study Takes Closer Look at Erbitux Efficacy in Patients with Specific KRAS Mutations (11-8-2010)

Although colorectal cancer patients with mutations in the KRAS gene tend not to respond to drugs such as Erbitux® (cetuximab), responsiveness may vary by the specific type of KRAS mutation. These results were published in the Journal of the American... Continue Reading

« Previous PageNext Page »